Turnstone Biologics Corp. announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced that Sammy Farah, M.B.A., Ph.D., President and Chief Executive Officer, will present at the upcoming Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, in Las Vegas, Nevada. The presentation will begin at 11:35 a.m. P.T. / 2:35 p.m. E.T.
To access a live webcast of the presentation, please visit the Events page in the Investors section of the Company’s website at www.turnstonebio.com. A webcast replay will be available for a limited period.
Members of Turnstone’s senior management will also be available for one-on-one meetings during the conference. Interested investors should contact their Bank of America Securities representative for further information.
About Turnstone
Turnstone Biologics is a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Turnstone’s next-generation TIL therapy is based upon the identification, selection and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TIL that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in multiple Phase 1 studies in patients with colorectal cancer, breast cancer, head and neck cancer, uveal melanoma, and cutaneous melanoma. The Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. For additional information about Turnstone, please visit www.turnstonebio.com, and follow us on LinkedIn.
Contact
Ahmed Aneizi
Investor Relations
Turnstone Biologics
(347) 897-5988
ahmed.aneizi@turnstonebio.com
